Compare
Pelthos Therapeutics Inc. vs Relay Therapeutics, Inc. vs LENZ Therapeutics, Inc. vs Lineage Cell Therapeutics, Inc.
| Latest fiscal year | Pelthos Therapeutics Inc. PTHS | Relay Therapeutics, Inc. RLAY | LENZ Therapeutics, Inc. LENZ | Lineage Cell Therapeutics, Inc. LCTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $16.80M | $15.36M | $19.09M | $14.56M |
| Revenue growth (YoY) | n/a | +53.4% | n/a | +53.2% |
| Gross margin | 76.3% (computed) | n/a | n/a | n/a |
| Operating margin | -193.1% | n/m | -477.5% | -251.6% |
| Net margin | -257.9% | n/m | -430.3% | -436.5% |
| Net income | -$43.32M | -$276.48M | -$82.13M | -$63.53M |
| EPS (Diluted) | -$23.04 | -$1.61 | -$2.85 | -$0.28 |
| Operating cash flow | -$22.59M | -$235.46M | -$69.17M | -$18.92M |
| Free cash flow | -$22.69M | -$235.87M | -$70.00M | -$19.44M |
| Cash & equivalents | $17.97M | $84.02M | $25.18M | $40.79M |
| Total assets | $130.40M | $621.33M | $305.88M | $112.58M |
| Total liabilities | $91.52M | $54.27M | $21.54M | $69.24M |
| Shareholders' equity | $38.88M | $567.06M | $284.34M | $43.35M |
| Return on year-end equity | -111.4% | -48.8% | -28.9% | -146.6% |
| Shares outstanding | 3.23M | 173.87M | 31.34M | 243.12M |
Revenue, most recent five fiscal years
| Fiscal year | Pelthos Therapeutics Inc. | Relay Therapeutics, Inc. | LENZ Therapeutics, Inc. | Lineage Cell Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $16.80M Ended 2025-12-31 | $15.36M Ended 2025-12-31 | $19.09M Ended 2025-12-31 | $14.56M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $10.01M Ended 2024-12-31 | $0 Ended 2024-12-31 | $9.50M Ended 2024-12-31 |
| 2 years earlier | n/a | $25.55M Ended 2023-12-31 | n/a | $8.95M Ended 2023-12-31 |
| 3 years earlier | n/a | $1.38M Ended 2022-12-31 | n/a | $14.70M Ended 2022-12-31 |
| 4 years earlier | n/a | $3.03M Ended 2021-12-31 | n/a | $4.34M Ended 2021-12-31 |